StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)

Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –

Krystal Biotech pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Krystal Biotech's pe ratio was 38.7× on Nov 11, 2026, against 32.7× a year earlier. Over the last 3 years it ranged from 30.0× to 459.6×, with a median of 45.6×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202638.7×+1.7
2025Dec 31, 202537.0×−49.1
2024Dec 31, 202486.0×–

More Krystal Biotech figures

See a number that looks wrong?